News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

Wireless Patient Monitoring and Diagnostic Systems Using MBANs Should Be on the Radar Screens of Pathologists and Clinical Laboratory Professionals

Experts are excited about the swift development of wireless remote monitoring of patients; companies expected to develop sensors that incorporate a wide range of biomarkers

Some experts predict that the era of wireless, remote monitoring of patients is almost upon us. It will require pathologists and medical laboratory professionals to learn a new acronym: MBAN, which stands for medical body area network.

There is keen interest in remote wireless monitoring systems. The concept is to free patients from the hospital bed and allow continuous remote monitoring, regardless of where the patient is located. For this reason, in just a few years and in many local markets, opportunities are likely to be ripe for pathologists and clinical laboratory teams to have a role in managing wireless medical devices that use MBANs. (more…)

Converging Technologies Enable Faster Diagnoses by Pathologists and Physicians

Innovative and inexpensive technologies hold the promise of instantaneous diagnosis while transforming conventional clinical laboratory tools

“Point-of-care pathology” may not be that far away! The convergence of medical and information technologies, the falling cost of computing, and the growing availability of miniaturization technologies make it increasingly possible for pathologists and physicians to make informed, on-the-spot diagnostic decisions about patient care.

A new wave of imaging technologies—including pathology tools—is poised to transform the practice of medicine, reported a recent story in the New York Times. Some of these technologies make it possible for pathologists and other physicians to view individual cells in situ and in vivo.

The NY Times story highlighted multiple research and development initiatives that have the same goal: reduce the time get an answer for tissue diagnosis and bring diagnostic tests to the patient. Some technologies would engage pathologists. Others reflect developments in radiology and imaging. (more…)

Quest Diagnostics Picks Rusckowski as New President and CEO to Lead the Nation’s Largest Clinical Pathology Company

Many challenges ahead for Rusckowski because of healthcare’s unfolding transformation

Yesterday, after the stock markets closed, Quest Diagnostics Incorporated (NYSE: DGX) issued a press release naming Stephen H. Rusckowski as its new President and CEO. He will assume his duties on May 1, 2012. Quest Diagnostics is the nation’s largest clinical laboratory company.

Along with the appointment of its new President and CEO, Quest Diagnostics also announced that Daniel C. Stanzione, Ph.D., would become the Non-Executive Chairman of the Board for the Madison, New Jersey-based company. Stanzione has served as a Director on the Quest Board since 2004.

To ensure an orderly transition, Surya N. Mohapatra, Ph.D., the current Chairman, President, and CEO, will continue his duties through April 30, 2012. It was on October 25, 2011, when Quest Diagnostics disclosed a succession plan and stated that Mohapatra, now 61 years old, would serve for an additional six months as the company conducted its search for another CEO.


Dako Announces Digital Pathology Agreements with Philips and Omnyx

Goal is to deliver integrated digital pathology solutions to clinical pathology laboratories

Yesterday, Dako announced separate digital pathology agreements with Royal Philips Electronics (NYSE: PHG) and Omnyx, LLC. Both the Philips and Omnyx agreements give each company access to Dako’s proprietary software algorithms and reagents used in tissue analysis for certain cancers.

In the deal between Philips and Dako, Philips plans to incorporate certain of Dako’s image analysis applications to the digital pathology system it is currently developing. Breast cancer is the diagnostic area covered by this new agreement. Philips will get access to Dako’s image analysis software for tissue-based breast cancers diagnosis, in tandem with Dako’s reagents for staining HER2, Estrogen Receptor (ER), Progesterone Receptor (PR), p53 and Ki-67 proteins.